{
    "nctId": "NCT01234402",
    "briefTitle": "Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients",
    "officialTitle": "An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or Icrucumab (IMC-18F1) in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 153,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The participant has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease\n* Has measurable or nonmeasurable disease\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Has received prior anthracycline therapy\n* Has received prior taxane therapy\n* Participants with human epidermal growth factor receptor-2 (HER2) positive disease must have progressed on or following trastuzumab\n* Participants with hormone receptor-positive disease must have progressed on or following hormone therapy\n* Has received \u2264 3 prior chemotherapy regimens in any setting (a regimen is defined as any agent\\[s\\] that has been administered for more than 1 cycle; sequential neoadjuvant/adjuvant treatment is considered 1 regimen)\n* Has completed any prior radiotherapy \u2265 4 weeks prior to randomization\n* Has completed any prior hormonal therapy \u2265 2 weeks prior to randomization\n* Has adverse events (AEs) that have resolved to Grade \u2264 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0) from all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy,or hormonal therapy\n* Has adequate hematologic, coagulation, hepatic and renal function\n* Does not have:\n\n  * cirrhosis at a level of Child-Pugh B (or worse) or\n  * cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis\n* Has urinary protein is \u2264 1+ on dipstick or routine urinalysis; if urine protein \u2265 2+, a 24-hour urine collection must demonstrate \\< 1000 mg of protein in 24 hours to allow participation in the study\n* Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medication\n\nExclusion Criteria:\n\n* Has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, curatively treated cervical carcinoma in situ, or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that there has been a disease-free interval for \\> 3 years\n* Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80\n* Has a known sensitivity to 5-fluorouracil (5-FU)\n* Has a known dihydropyrimidine dehydrogenase deficiency\n* Has received prior capecitabine treatment for advanced breast cancer\n* Has received investigational therapy within 2 weeks prior to randomization\n* Has received bevacizumab within 4 weeks prior to randomization\n* Has received more than 1 prior antiangiogenic agent for breast cancer\n* Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or Icrucumab (IMC-18F1), or other agents that specifically target vascular endothelial growth factor (VEGF)\n* Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention\n* Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders\n* Has experienced a Grade \u2265 3 bleeding event within 3 months prior to randomization\n* Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant\n* Has an uncontrolled intercurrent illness, including, but not limited to uncontrolled hypertension, symptomatic anemia, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorder in the opinion of the investigator\n* Has experienced any arterial thrombotic or thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months prior to randomization\n* Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease\n* Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy\n* Has received a prior allogeneic organ or tissue transplantation\n* Has undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization\n* Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization\n* Has known HIV or AIDS infection\n* Has an elective or planned major surgery to be performed during the course of the trial\n* Participant is pregnant or lactating",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}